Annovis Bio Inc

NYSE ANVS

Data sourced from

and

Download Data

Annovis Bio Inc EBITDA for the quarter ending March 31, 2024: USD -7.81 M

Annovis Bio Inc EBITDA is USD -7.81 M for the quarter ending March 31, 2024, a 21.66% change year over year. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, measures a company's operating performance by excluding non-operating expenses.

Annovis Bio Inc EBITDA for the quarter ending March 31, 2023 was USD -9.97 M, a -68.58% change year over year.
Annovis Bio Inc EBITDA for the quarter ending March 31, 2022 was USD -5.91 M, a -84.82% change year over year.
Annovis Bio Inc EBITDA for the quarter ending March 31, 2021 was USD -3.20 M, a -701.52% change year over year.
Annovis Bio Inc EBITDA for the quarter ending March 31, 2020 was USD -399.22 K, a -113.73% change year over year.

NYSE: ANVS

Annovis Bio Inc

CEO	Dr. Maria L. Maccecchini Ph.D.
IPO Date	Feb. 12, 2010
Location	United States
Headquarters	1055 Westlakes Drive, Berwyn, PA, United States, 19312
Employees	6
Sector	Healthcare
Industry	Biotechnology

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Key trends